^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
Cantrixil (TRX-E-002-1)
i
Other names: TRXE-002, TRXE-002-1, TRXE002, TRX-E-002-1, TRXE-002-1 encapsulated in a cyclodextrin envelope, TRX1, TRXE 002 1, TRX E 002 1
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Kazia, Vivesto, Yale University
Drug class:
Cell death stimulant
Related drugs:
over5years
[VIRTUAL] TRX-E-002-1 in treatment-refractory ovarian cancer - 3-month follow-up results from a phase I study dose escalation phase (AACR-II 2020)
IP administered TRX-E-002-1 as a first-in-class, dual acting, anti-cancer therapy has preliminary activity for the treatment of platinum resistant ovarian cancer for patients who have demonstrated resistance to a range of prior treatments.
P1 data • PARP Biomarker
|
CD44 (CD44 Molecule)
|
Cantrixil (TRX-E-002-1)
over5years
Phase I Study of Cantrixil in Patients With Ovarian Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer. (clinicaltrials.gov)
P1, N=28, Completed, Kazia Therapeutics Limited | Active, not recruiting --> Completed | Trial primary completion date: Dec 2019 --> Mar 2020
Clinical • Trial completion • Trial primary completion date
|
BRCA (Breast cancer early onset)
|
Cantrixil (TRX-E-002-1)
Share via
